Results 201 to 210 of about 68,610 (290)
G protein-coupled receptors in prostate cancer: research progress and therapeutic targets. [PDF]
Xiong W, Zhou B, Shi J, Ni D, Xiong Z.
europepmc +1 more source
This review highlights mitochondrial dysfunction as a central driver of pancreatic β cell failure in diabetes, caused by disrupted mitochondrial quality control (MQC), oxidative stress, and impaired organelle communication. Emerging therapies, such as DRAK2 inhibitors and metabolic reprogramming agents, show promise in restoring β cell function by ...
Ruihan Li +5 more
wiley +1 more source
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]
Versteeg JW +5 more
europepmc +1 more source
We developed a LASSO‐based approach to uncover a three‐layered “fan‐in fan‐out” network architecture for complex traits like yeast aging, showing that peripheral genes influence lifespan indirectly through master regulators, which converge on core functional modules (e.g., stress response, autophagy).
Meng Ma +12 more
wiley +1 more source
How to evaluate rare disease policy effectiveness based on policy modeling consistency (PMC) index model: A quantitative assessment of policy implementation in China. [PDF]
Zhao Y +6 more
europepmc +1 more source
Abstract Aims To describe differences in the expression of genes encoding cannabinoid receptors (CNR1, CNR2), the associated receptor GRP55 and the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL) between individuals with alcohol use disorder (AUD) and controls in key mesocorticolimbic brain regions.
María Salud García‐Gutiérrez +5 more
wiley +1 more source
HTA Evidence in Rare Diseases: Just Rare or Also Special? [PDF]
Basu A +3 more
europepmc +1 more source
Pharmacogenetic Interventions, Orphan Groups, and Distributive Justice: The Role of Cost-Benefit Analysis [PDF]
Rai, Arti K.
core +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
ABSTRACT Globally, millions of children are adopted or placed in alternative care settings (i.e., residential, foster, or kinship care). The current study explores the factors leading to separation from parents and adoption or placement in alternative care by investigating orphanhood status, perceived antecedents to placement, types of alternative care
Nicole Gilbertson Wilke +2 more
wiley +1 more source

